PROCEPT BioRobotics Corporation

NASDAQ:PRCT

Medical - Devices

Healthcare
$25.18 +0.89%

+$0.19 today

Market cap
$1.45B
Beta
0.85
P/E (TTM)
-11.6
EPS (TTM)
-$1.81
52W Low $19.35High $62.17

Volume 2.05M

Average 1.46M

PRCT EBITDA Margin

EBITDA as a percentage of revenue.

PROCEPT BioRobotics CorporationNASDAQ: PRCT

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to -35.0%

EBITDA Margin was -35.0% in Q1 FY2026, down 2.6 pp from a year earlier. On a trailing-twelve-month basis it was -28.6%, up 3.8 pp year over year. Over 3 fiscal years it widened by 77.8 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 10 analysts of -20.7% for the fiscal year ending Dec 2026, up from -27.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-35.0%+0.4 pp QoQ
Last fiscal yearDec 2025
-27.7%+8.8 pp YoY
LTMMar 2026
-28.6%+3.8 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-2.6 pp-3.9 pp-1.3 pp
1 year+8.8 pp+7.0 pp-1.8 pp
3 years+77.8 pp+22.7 pp-55.1 pp
5 years+38.1 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-27.7%
Year-over-year change
+8.8pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How PRCT compares with its peers on the latest reported figures

  • PRCT's LTM Mar 2026 EBITDA Margin of -28.6% is the 2nd highest of the 5 companies compared; the peer median is -45.7%.
  • Its year-over-year change of +3.8 pp is the 2nd highest of 3, against a peer median of +41.5 pp.
  • Over three fiscal years its change of +77.8 pp compares with a peer median of +19.4 pp.
PRCT Competitors Peer median
EBITDA Margin for PRCT and competitors
Company Period LTM level YoY 3-year change
SSIISS Innovations International, Inc.LTM Mar 2026-7.7% +82.2 pp+350.1 pp
PRCTPROCEPT BioRobotics CorporationLTM Mar 2026-28.6% +3.8 pp+77.8 pp
FOCLEDAP TMS S.A. American Depositary SharesLTM Mar 2026-33.2% —-33.8 pp
CLPTClearPoint Neuro, Inc.LTM Mar 2026-58.2% +0.7 pp+19.4 pp
MBOTMicrobot Medical Inc.LTM Mar 2026-13493.3% ——
Peer median (excluding PRCT) -45.7%+41.5 pp+19.4 pp

Competitors are the stored peer set for PRCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue34.47M75.01M136.19M224.5M308.05M
Cost of Revenue18.61M37.93M65.14M87.4M111.83M
Gross Profit15.87M37.09M71.05M137.1M196.23M
Gross Margin46.0%49.4%52.2%61.1%63.7%
Research & Development18.99M28.98M48.45M62.3M71.28M
Selling, General & Admin51.04M88.83M131.77M171.42M228.81M
Operating Expenses70.03M117.81M180.22M233.71M300.09M
Depreciation & Amortization3.32M2.84M3.81M5.23M6.39M
EBITDA(50.72M)(79.13M)(98.1M)(82M)(85.41M)
EBITDA Margin-147.1%-105.5%-72.0%-36.5%-27.7%
Operating Income(54.16M)(80.72M)(109.17M)(96.61M)(103.86M)
Operating Margin-157.1%-107.6%-80.2%-43.0%-33.7%
Interest Income76K2.5M7.55M10.9M12.22M
Interest Expense5.81M5.18M4M4.18M3.59M
Other Income / Expenses(5.69M)(6.43M)3.27M5.2M8.48M
Income Before Tax(59.85M)(87.15M)(105.9M)(91.41M)(95.38M)
Pre-Tax Margin-173.6%-116.2%-77.8%-40.7%-31.0%
Income Tax Expense0000190K
Net Income(59.85M)(87.15M)(105.9M)(91.41M)(95.57M)
Net Margin-173.6%-116.2%-77.8%-40.7%-31.0%
EPS (Basic)(1.37)(1.96)(2.24)(1.75)(1.72)
EPS (Diluted)(1.37)(1.96)(2.24)(1.75)(1.72)
Weighted Avg Shares43.7M44.4M47.26M52.13M55.54M
Weighted Avg Shares (Diluted)43.7M44.4M47.26M52.13M55.54M

PROCEPT BioRobotics Corporation

NASDAQ:PRCT

Intrinsic Alpha fair value

Locked

Current Price

$25.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.